Product Information
SUMATRIPTAN 6 MG/0.5 ML VIAL is a generic product labeled by Xellia Pharmaceuticals USA LLC, priced at $14.9345 per ML under NDC 70594006802. Its NADAC has been published 226 times since Jun 8, 2022.
FDA first approved this application on Jul 13, 2021. Its Orange Book therapeutic-equivalence code is AP.
Strength
6 mg/.5mL
Manufacturer
Xellia Pharmaceuticals USA LLCNDC
70594006802
Classification
Generic
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA213998FDA Approved
7/13/2021
TE Code
AP
On Market Since
1/1/2022
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN 6 MG/0.5 ML VIAL has been published 226 times since Jun 8, 2022, and over the history we have for it it has declined 20.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $14.9345 per ML |
|---|---|
| All-time high | $20.1296 (Jun 14, 2023) |
| All-time low | $12.4674 (May 22, 2024) |
| 52-week high | $15.2668 |
| 52-week low | $13.7735 |
| Median price | $15.5498 |
| Average price | $16.0558 |
| Largest weekly change | +31.8% (Feb 22, 2023) |
| Weeks tracked | 226 |
| Tracking since | Jun 8, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the SUMATRIPTAN SUCCINATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xellia Pharmaceuticals USA LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
SUMATRIPTAN SUCCINATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN 6 MG/0.5 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN 6 MG/0.5 ML VIAL, manufactured by Xellia Pharmaceuticals USA LLC, is $14.9345 per ML (NDC 70594006802), effective Sep 30, 2026.
How has the price of SUMATRIPTAN 6 MG/0.5 ML VIAL changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN 6 MG/0.5 ML VIAL has declined 20.6%. It has been tracked across 226 weekly CMS publications since Jun 8, 2022.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN 6 MG/0.5 ML VIAL?
Since Jun 8, 2022, the NADAC for SUMATRIPTAN 6 MG/0.5 ML VIAL has ranged from a low of $12.4674 (May 22, 2024) to a high of $20.1296 (Jun 14, 2023), with a median of $15.5498 per ML.
Are there cheaper alternatives to SUMATRIPTAN 6 MG/0.5 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of SUMATRIPTAN 6 MG/0.5 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SUMATRIPTAN 6 MG/0.5 ML VIAL?
SUMATRIPTAN 6 MG/0.5 ML VIAL (NDC 70594006802) is labeled by Xellia Pharmaceuticals USA LLC, and CMS classifies it as a generic product.